期刊文献+

早期肺癌手术治疗后的局部复发情况分析 被引量:4

Analysis of early lung cancer with local recurrence after surgical treatment
下载PDF
导出
摘要 目的探讨早期肺癌术后局部复发的相关因素。方法收集在该院定期复查确诊的262例临床I期肺癌术后复发的病例,对术后局部复发的因素进行统计分析。结果262例患者局部复发25例,复发率为9.5%(25/262);复发时间3-46个月,平均(22.8±10.3)个月;不同性剐和年龄肺癌患者的术后局部复发率无显著性差异(P〉0.05),而不同病理类型、手术方式、分化程度、病变部位、术前CEA浓度和肿瘤最大径的术后局部复发率有显著性差异(P〈0.05或0.01)。术前CEA浓度和分化程度进入最佳回归方程。结论病理类型、手术方式、分化程度、病变部位、术前CEA浓度和肿瘤最大径是早期肺癌术后局部复发的危险因素,术前CEA浓度和分化程度是高危独立因素。 [ Objective] To investigate the correlation factor of early lung cancer with local recurrence after surgical treatment. [Methods] Retrospective analysis of 262 cases of stage- I lung cancer with local recun'ence postoperatively was rechecked and diagnosed in our hospital. Statistical analysis of the relevant factors of local recurrence postoperatively was made. [Results] There were 25 cases local recurrence in 262 cases, the recurrence rate was 9.5% (25/262); recurrence time at 3 to 46 months, an average (22.8±10.3) months; local recurrence of iung cancer patients showed no significant difference in different gender, age (P 〉0.05), the local recurrence rates were signifi- candy different in different pathological types, surgical methods, degree of differentiation, diseased region, preopera- tive CEA concentration and maximum tumor diameter (P 〈0.05 or 0.01). Preoperative CEA concentration and the degree of differentiation were the best regression equation. [ Conclusion ] The pathological types, surgical method, degree of differentiation, diseased region, preoperative CEA concentration and maximum tumor diameter are early Hsk factors of local recurrence in lung cancer, preoperative CEA concentration and the degree of differentiation are independent risk factors.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2011年第18期2161-2163,共3页 China Journal of Modern Medicine
关键词 早期肺癌 手术 局部复发 early lung cancer surgical local recurrence
  • 相关文献

参考文献5

二级参考文献61

  • 1朱文,周清华.肺癌病因学和遗传易感性研究进展[J].中国肺癌杂志,2005,8(5):385-389. 被引量:10
  • 2王瑾,许峰,周清华.肺癌流行病学研究进展[J].中国肺癌杂志,2005,8(5):395-400. 被引量:57
  • 3潭壮生.吸烟和饮酒现状及其危害和对策[J].中国全科医学,2006,9(13):1082-1084. 被引量:21
  • 4廖美琳.小细胞肺癌内科治疗的新选择[J].肿瘤,2006,26(7):587-591. 被引量:10
  • 5RAMASWAMY G,NATHAN P,DANIEL M,et al.Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J].J Clin Oncol,2006,24(28):4539-4544.
  • 6SIMON G R,WAGNER H.Small cell lung cancer[J].Chest,2003,123(Suppl):259S-271S.
  • 7廖美琳 徐昌文 黄偶麟 等.SCLC结合手术的多学科治疗.中华结核和呼吸杂志,1987,10:129-132.
  • 8KUBOTA K,NISHIWAKI Y,SUGIURA T,et al.Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limi-ted-stage small cell lung cancer:Japan Clinical Oncology Group 9903[J].Clin Cancer Res,2005,11(15):5534-5538.
  • 9FRIED D B,MORRIS D E,POOLE C,et al.Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer[J].J Clin Oncol,2004,22(23):4837-4835.
  • 10SCHREIBER D,RINEER J,VONGTAMA D,et al.Surgery for limited-stage small cell lung cancer,should the paradigm shift? A SEER-based analysis[J].J Clin Oncol,2008,26(15S):7525.

共引文献58

同被引文献16

  • 1张德超,毛友生,黄国俊.中国肺癌外科治疗概况与进展[J].中国肺癌杂志,2005,8(6):557-562. 被引量:28
  • 2Boyd JA,Hubbs JL,Kim DW,et al.Timing of local and distantfailure in resected lung cancer: implications for reported rates of localfaiiure[J].J Thorac Oncol, 201 0, 5(2): 211-214.
  • 3Arriagada R,Bergman B,Dunant A,et al.Cisplatin—based adjuvantchemotherapy in patients with completely resected non—small—cell lungcancer[J], N Engl J Med, 2004, 350(4). 351-360.
  • 4Douillard JY(RoselI R,De Lena M,et al. Adjuvant vinorelbineplus cisplatin versus observation in patients with completely resectedstage IB-A non—small—cell lung cancer (Adjuvant Navelbine InternationalTrialist Association [ANITA]).a randomised controlled tria![J].Lancet Oncol,2006,7(9):719-727.
  • 5Pignon JP,Tn'bodet H.Scagfiotti GV,et af.Lung adjuvant cisplatinevaluation:a pooled analysis by the LACE Collaborative Group[J].J Clin .0ncol,2008,26(21):3552-3559.
  • 6Strauss GM,2 nd HJE,Maddau9 MA,et al .Adjuvant paclitaxel pluscarbopiatin compared with observation in stage IB non—small-cell lung cancer:CALGB 9633 with the Cancer and Leukemia Group B,Radiation TherapyOncology Group, and North Central Cancer Treatment Group Study Groups[J].J Clin Oncol,2008,26(31):5043-5051 .
  • 7Arriagada R,Dunant A, Pignon JP,et al .Long-term results of theinternational adjuvant lung cancer trial evaluating adjuvant Cisplatin—basedchemotherapy in resected lung cancer[J].J Clin Oncol,2010,28(1).35-42.
  • 8Varlotto JM,Recht A,Flick.inger JC,et ai. Factors associated withlocal and distant recurrence and survival in patients with resected nonsmallcell lung cancer[J],Cancer,2009,1 1 5(5). 1 059—1 069.
  • 9Machtay M, Lee JH, Shrager JB,et al. Risk of death fromintercurrent disease is not excessively increased by modern postoperativeradiotherapy for high-risk resected non—small-ceil lung carcinoma[J],J ClinOncol, 2001 ,19(19):3912-3917.
  • 10Koo HK,Jin SM,Lee CH.Factors associated with recurrence inpatients with curatively resected stage l-ll lung cancer[J].Lung Cancer,2011,73(2):222-229.

引证文献4

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部